Kidney Cancer News and Research

RSS

Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.

New initiative aims to transform care for early-onset cancer patients

More people under age 50 are developing cancer, and with that comes a shift in the model of care needed to serve this unique cancer patient population – including early access to fertility counseling, universal genomic testing to identify underlying genetic drivers, support resources to address long-term survivorship considerations, and community education regarding early detection and screening.

15 Dec 2025

'Myeloid mimicry' identified as driver of immunotherapy resistance in renal medullary carcinoma

Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism called "myeloid mimicry" to hide from the immune system and promote disease hyper progression after immunotherapy, highlighting specific targets that overcome treatment resistance in preclinical models.

25 Nov 2025

TROP2 identified as a promising therapeutic target for renal medullary carcinoma

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive form of kidney cancer, leading to the identification of TROP2 as a promising therapeutic target.

30 Oct 2025

Researchers engineer a tool to dismantle cancer's RNA-built growth hubs

In a city, coworking hubs bring people and ideas together. Inside cancer cells, similar hubs form-but instead of fueling progress, they supercharge disease. That's what researchers at the Texas A&M University Health Science Center (Texas A&M Health) have discovered inside the cells of a rare and aggressive kidney cancer.

21 Oct 2025

Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and potentially life-threatening neuroendocrine tumors.

18 Oct 2025

Targeted therapy combination shows superior outcomes in advanced kidney cancer

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney cancer – whose disease progressed following immunotherapy.

18 Oct 2025

NCCN enhances widely used breast cancer guidelines with advanced digital features

Today, the National Comprehensive Cancer Network® (NCCN®)-a nonprofit responsible for globally utilized guidelines for cancer care-is sharing new NCCN Guidelines Navigator™ resources for breast cancer treatment as well as genetic/familial high-risk assessment, during Breast Cancer Awareness Month.

7 Oct 2025

Modifiable risk factors could double global kidney cancer cases by 2050

Modifiable risk factors such as obesity, smoking, lack of exercise, diabetes and hypertension are projected to be one of the main drivers of a steep rise in kidney cancer cases, doubling the amount worldwide over the next 25 years, according to a new study recently published in European Urology.

26 Sep 2025

PRMT5 inhibition induces ferroptosis and enhances immunotherapy efficacy in renal cell carcinoma

Ferroptosis, a regulated cell death mechanism, is emerging as a promising target for cancer therapy. The process is mediated by the activity of acyl-CoA synthetase family member 4 (ACSL4) protein.

22 Sep 2025

New off-the-shelf immunotherapy for metastatic kidney cancer could help improve outcomes

UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective environment - all without the need to customize treatment for each individual patient.

29 Aug 2025

3D-printed kidney tumors offer a new tool in the fight against renal cancer

Scientists at Tsinghua University have developed a method to grow kidney tumors in the lab using cells from real patients, offering a potential new tool in the fight against renal cancer.

12 Aug 2025

AI and extended reality successfully train surgical trainees without instructors

Mount Sinai researchers have demonstrated the effectiveness of teaching surgical trainees a difficult procedure using artificial intelligence (AI) algorithms and an extended-reality headset without the presence of an instructor.

6 Aug 2025

Advanced form of AI opens door to personalized cancer care

What if a computer could read a patient's medical notes and help doctors determine important information for their treatment?

1 Aug 2025

Two-drug combo shows durable benefit in advanced kidney cancer

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.

1 Aug 2025

Amid PFAS fallout, a Maine doctor navigates medical risks with her patients

When Lawrence and Penny Higgins of Fairfield, Maine, first learned in 2020 that high levels of toxic chemicals called PFAS taint their home's well water, they wondered how their health might suffer.

22 Jul 2025

Rare kidney cancer evades immune system in unique ways

Cancer fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those that are present are indifferent to the tumor threat and traditional immune therapies, revealing the need for new targets and treatments.

4 Jul 2025

Early life exposure to PFHxA may impact male brain development

"Forever chemicals" or per- and polyfluoroalkyl substances (PFAS) have been widely used in consumer and industrial products for the better part of a century, but do not break down in the natural environment.

4 Jul 2025

Global cancer experts gather in Kenya to improve care across Sub-Saharan Africa

The National Comprehensive Cancer Network (NCCN)-an alliance of leading cancer centers in the United States-is joining the African Cancer Coalition (ACC) to update cancer treatment recommendations during the American Cancer Society (ACS) 2025 Global Academy Regional Workshop: Sub-Saharan Africa, in Nairobi, Kenya, June 9-11.

10 Jun 2025

Wilms tumor found to contain millions of genetic changes

Researchers have uncovered that some childhood cancers have a substantially higher number of DNA changes than previously thought, changing the way we view children's tumours and possibly opening up new or repurposed treatment options.

29 May 2025

MD Anderson researchers present promising clinical trial results at AACR 2025

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025.

26 Apr 2025